Sample characteristics stratified by VTE phenotype
| . | Isolated PE(n = 96) . | DVT-associated PE(n = 276) . | Isolated DVT(n = 160) . |
|---|---|---|---|
| Female, % (n) | 52.1 (50) | 42 (116) | 41.2 (66) |
| Age, y | 61.3 (17.7) | 61.7 (15.6) | 56 (16.1) |
| Body mass index, kg/m2 | 28 (7.3) | 30.3 (5.9) | 27.8 (5.5) |
| VTE risk factors | |||
| History of VTE, % (n) | 16.9 (15) | 34.7 (91) | 33.3 (53) |
| History of DVT, % (n) | 13.5 (12) | 29.9 (78) | 32.7 (52) |
| History of PE, % (n) | 5.4 (5) | 14.9 (39) | 5.7 (9) |
| Pregnancy, % (n) | 0 (0) | 0.7 (2) | 1.9 (3) |
| Recent immobilization, % (n) | 11.8 (11) | 14.2 (38) | 14.4 (23) |
| Recent long-distance travel, % (n) | 10.9 (10) | 12.2 (32) | 16.9 (27) |
| Recent surgery, % (n) | 8.6 (8) | 3.7 (10) | 4.4 (7) |
| Recent trauma, % (n) | 3.2 (3) | 4.9 (13) | 6.9 (11) |
| Diagnosed thrombophilia, % (n) | 0 (0) | 3.3 (7) | 5.8 (9) |
| Genotyping | |||
| rs6025 (factor V Leiden) | |||
| Heterozygous carrier, % (n) | 3.8 (3) | 14.1 (35) | 19 (27) |
| Homozygous carrier, % (n) | 0 (0) | 0.8 (2) | 1.4 (2) |
| rs1799963 (prothrombin G20210A) | |||
| Heterozygous carrier, % (n) | 1.3 (1) | 6.5 (16) | 6.4 (9) |
| Homozygous carrier, % (n) | 0 (0) | 0.4 (1) | 0 (0) |
| Cardiovascular risk factors | |||
| Active smoking, % (n) | 12.4 (11) | 14.3 (36) | 25 (40) |
| Arterial hypertension, % (n) | 49.5 (46) | 59.9 (154) | 35.7 (56) |
| Diabetes mellitus, % (n) | 16.1 (15) | 14.4 (37) | 9.4 (15) |
| Obesity, % (n) | 19.8 (19) | 45.3 (120) | 31.8 (47) |
| Comorbidities | |||
| Atrial fibrillation, % (n) | 5.4 (5) | 5.1 (13) | 2.5 (4) |
| Chronic kidney disease, % (n) | 7.6 (7) | 5.4 (14) | 3.8 (6) |
| Chronic liver disease, % (n) | 2.2 (2) | 7.4 (19) | 3.8 (6) |
| Chronic pulmonary disease, % (n) | 17.2 (16) | 10 (27) | 11.4 (18) |
| Congestive heart failure, % (n) | 9.7 (9) | 5.6 (14) | 1.9 (3) |
| Coronary artery disease, % (n) | 7.7 (7) | 7.5 (19) | 5.7 (9) |
| History of stroke, % (n) | 4.3 (4) | 7.8 (20) | 0.6 (1) |
| Peripheral artery disease, % (n) | 11.4 (5) | 3 (5) | 3.2 (5) |
| Pulmonary hypertension, % (n) | 1.1 (1) | 1.6 (4) | 0.6 (1) |
| Laboratory markers | |||
| Creatinine, mg/dL | 0.9 (0.8-1.1) | 0.9 (0.8-1.2) | 0.9 (0.8-1) |
| C-reactive protein, mg/L | 14 (3.9-62.8) | 24 (9.1-54.8) | 6.2 (2.7-14.7) |
| D-dimer, mg/L | 2.3 (1.2-7.2) | 4.7 (2.7-11.1) | 1.4 (0.8-4) |
| eGFR, mL/min/1.73 m2 | 74.8 (24.5) | 74.6 (22.4) | 85.1 (22.9) |
| Hematocrit, % | 39.7 (4.5) | 40.9 (5.2) | 41.1 (4.7) |
| Leukocytes, /nL | 8.6 (6.7-11.4) | 9.3 (7.1-11.6) | 7.4 (6-9.5) |
| Platelet count, /nL | 239 (204-289) | 234 (185-287) | 237 (188-290) |
| Troponin I, pg/mL | 10.3 (2.9-38.6) | 16.3 (4.2-60.2) | 2.2 (1.5-4.3) |
| Medication | |||
| Antithrombotic agents (B01A), % (n) | 88.5 (85) | 91.7 (253) | 76.2 (122) |
| Anticoagulants (B01A, excluding B01AC), % (n) | 76 (73) | 81.9 (226) | 69.4 (111) |
| Antiplatelet agents (B01AC), % (n) | 33.3 (32) | 35.5 (98) | 13.1 (21) |
| NSAIDs (M01A), % (n) | 1 (1) | 5.4 (15) | 6.2 (10) |
| Contraceptives (G03AA, G02BB), % (n) | 5.2 (5) | 3.3 (9) | 6.9 (11) |
| Corticosteroids (H02A), % (n) | 7.3 (7) | 9.1 (25) | 5.6 (9) |
| . | Isolated PE(n = 96) . | DVT-associated PE(n = 276) . | Isolated DVT(n = 160) . |
|---|---|---|---|
| Female, % (n) | 52.1 (50) | 42 (116) | 41.2 (66) |
| Age, y | 61.3 (17.7) | 61.7 (15.6) | 56 (16.1) |
| Body mass index, kg/m2 | 28 (7.3) | 30.3 (5.9) | 27.8 (5.5) |
| VTE risk factors | |||
| History of VTE, % (n) | 16.9 (15) | 34.7 (91) | 33.3 (53) |
| History of DVT, % (n) | 13.5 (12) | 29.9 (78) | 32.7 (52) |
| History of PE, % (n) | 5.4 (5) | 14.9 (39) | 5.7 (9) |
| Pregnancy, % (n) | 0 (0) | 0.7 (2) | 1.9 (3) |
| Recent immobilization, % (n) | 11.8 (11) | 14.2 (38) | 14.4 (23) |
| Recent long-distance travel, % (n) | 10.9 (10) | 12.2 (32) | 16.9 (27) |
| Recent surgery, % (n) | 8.6 (8) | 3.7 (10) | 4.4 (7) |
| Recent trauma, % (n) | 3.2 (3) | 4.9 (13) | 6.9 (11) |
| Diagnosed thrombophilia, % (n) | 0 (0) | 3.3 (7) | 5.8 (9) |
| Genotyping | |||
| rs6025 (factor V Leiden) | |||
| Heterozygous carrier, % (n) | 3.8 (3) | 14.1 (35) | 19 (27) |
| Homozygous carrier, % (n) | 0 (0) | 0.8 (2) | 1.4 (2) |
| rs1799963 (prothrombin G20210A) | |||
| Heterozygous carrier, % (n) | 1.3 (1) | 6.5 (16) | 6.4 (9) |
| Homozygous carrier, % (n) | 0 (0) | 0.4 (1) | 0 (0) |
| Cardiovascular risk factors | |||
| Active smoking, % (n) | 12.4 (11) | 14.3 (36) | 25 (40) |
| Arterial hypertension, % (n) | 49.5 (46) | 59.9 (154) | 35.7 (56) |
| Diabetes mellitus, % (n) | 16.1 (15) | 14.4 (37) | 9.4 (15) |
| Obesity, % (n) | 19.8 (19) | 45.3 (120) | 31.8 (47) |
| Comorbidities | |||
| Atrial fibrillation, % (n) | 5.4 (5) | 5.1 (13) | 2.5 (4) |
| Chronic kidney disease, % (n) | 7.6 (7) | 5.4 (14) | 3.8 (6) |
| Chronic liver disease, % (n) | 2.2 (2) | 7.4 (19) | 3.8 (6) |
| Chronic pulmonary disease, % (n) | 17.2 (16) | 10 (27) | 11.4 (18) |
| Congestive heart failure, % (n) | 9.7 (9) | 5.6 (14) | 1.9 (3) |
| Coronary artery disease, % (n) | 7.7 (7) | 7.5 (19) | 5.7 (9) |
| History of stroke, % (n) | 4.3 (4) | 7.8 (20) | 0.6 (1) |
| Peripheral artery disease, % (n) | 11.4 (5) | 3 (5) | 3.2 (5) |
| Pulmonary hypertension, % (n) | 1.1 (1) | 1.6 (4) | 0.6 (1) |
| Laboratory markers | |||
| Creatinine, mg/dL | 0.9 (0.8-1.1) | 0.9 (0.8-1.2) | 0.9 (0.8-1) |
| C-reactive protein, mg/L | 14 (3.9-62.8) | 24 (9.1-54.8) | 6.2 (2.7-14.7) |
| D-dimer, mg/L | 2.3 (1.2-7.2) | 4.7 (2.7-11.1) | 1.4 (0.8-4) |
| eGFR, mL/min/1.73 m2 | 74.8 (24.5) | 74.6 (22.4) | 85.1 (22.9) |
| Hematocrit, % | 39.7 (4.5) | 40.9 (5.2) | 41.1 (4.7) |
| Leukocytes, /nL | 8.6 (6.7-11.4) | 9.3 (7.1-11.6) | 7.4 (6-9.5) |
| Platelet count, /nL | 239 (204-289) | 234 (185-287) | 237 (188-290) |
| Troponin I, pg/mL | 10.3 (2.9-38.6) | 16.3 (4.2-60.2) | 2.2 (1.5-4.3) |
| Medication | |||
| Antithrombotic agents (B01A), % (n) | 88.5 (85) | 91.7 (253) | 76.2 (122) |
| Anticoagulants (B01A, excluding B01AC), % (n) | 76 (73) | 81.9 (226) | 69.4 (111) |
| Antiplatelet agents (B01AC), % (n) | 33.3 (32) | 35.5 (98) | 13.1 (21) |
| NSAIDs (M01A), % (n) | 1 (1) | 5.4 (15) | 6.2 (10) |
| Contraceptives (G03AA, G02BB), % (n) | 5.2 (5) | 3.3 (9) | 6.9 (11) |
| Corticosteroids (H02A), % (n) | 7.3 (7) | 9.1 (25) | 5.6 (9) |
Ranges in parentheses denote interquartile ranges and are shown for non-normally distributed variables. Single numbers in parentheses indicate the SD, shown for normally distributed variables. Percentages were calculated based on non-missing data. Individuals with active cancer were excluded from this analysis. All information regarding morbidity, cardiovascular risk factors, and VTE-specific risk factors was determined anamnestically and from the available medical files. Complete or lower limb immobilization, travel, surgery, and trauma were considered recent if they had occurred within 30 days before the baseline event. For medications, Anatomic Therapeutic Chemical (ATC) codes are shown beside the class in parentheses.
eGFR, estimated glomerular filtration rate; NSAIDs, nonsteroidal anti-inflammatory drugs.